Efficacy, safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir for HIV pre-exposure prophylaxis in transgender women: a secondary analysis of the HPTN 083 trialMark A. Marzinke, Sybil Hosek, Steven A. Safren et al.|The Lancet HIV|2023Cited by 14
HIV DNA Levels in Persons Who Acquired HIV in the Setting of Long-Acting Cabotegravir for HIV Prevention: Analysis of Cases from HPTN 083 and 084Jessica M. Fogel, Deborah Persaud, Estelle Piwowar‐Manning et al.|AIDS Research and Human Retroviruses|2024Cited by 5